Dermatology

Latest News

eye on pharma banner
Eye on Pharma: High-Strength Trastuzumab Biosimilar; Originator Coverage Removals; CHMP Aflibercept Opinion

October 3rd 2024

The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some preferred drug lists in favor of biosimilars and Evernorth will offer an interchangeable ustekinumab biosimilar at no cost to patients; Samsung Bioepis received a positive regulatory opinion for its aflibercept biosimilar.

FDA Approved graphic over a provider | Image credit: wladimir1804 - stock.adobe.com
Fourth Ustekinumab Biosimilar, Otulfi, Approved in US

September 30th 2024

doctor talking to patient | image credit: New Africa - stock.adobe.com
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study

September 28th 2024

Eye on Pharma banner
Eye on Pharma: EC Approved Ustekinumab; Zymfentra Expansion; Biosimilar Policy Briefing

September 26th 2024

CFB Q&A with Sophia Humphreys, PharmD | Background image credit: ipopba - stock.adobe.com
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys

September 16th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.